Background: It is not well known whether prestroke antiplatelet agents (PAs) are associated with the subtypes of ischemic stroke. Methods: We screened patients in a hospital-based stroke registry. Patients who were admitted with a diagnosis of first-time ischemic stroke within 5 days of symptom onset were included. Ischemic stroke subtypes were classified in accordance with the Trial of ORG 10172 in Acute Stroke Treatment classification based on stroke mechanism: large-artery atherosclerosis (LA), cardioembolism (CE), small vessel occlusion (SVO), other determined (OC) or undetermined causes (UC). Multinomial logistic regression analyses were performed to evaluate the effect of PA on stroke subtypes before and after propensity score matching. Results: Among 3,025 patients, 748 (24.7%) were taking antiplatelet agents prior to stroke. After propensity score matching, 1,190 patients were ultimately included. The PA group was associated with strokes caused by SVO rather than LA in multinomial logistic regression of an unmatched dataset. However, multivariable analysis after propensity score matching demonstrated that PA use was associated with a higher probability of SVO and CE (OR 2.05, p < 0.001 and OR 1.62, p = 0.05, respectively) compared with LA. Conclusions: PAs were associated with specific index stroke subtypes.

Keywords:
Ischemic stroke, Subtypes, Prestroke antiplatelet agents
1.
Pujol Lereis VA, Ameriso S, Povedano GP, Ameriso SF: Ischemic stroke in patients receiving aspirin. J Stroke Cerebrovasc Dis 2012;21:868-872.
2.
Islam MS, Anderson CS, Hankey GJ, Hardie K, Carter K, Broadhurst R, Jamrozik K: Trends in incidence and outcome of stroke in Perth, Western Australia during 1989 to 2001: the Perth community stroke study. Stroke 2008;39:776-782.
3.
Béjot Y, Aboa-Eboulé C, de Maistre E, Jacquin A, Troisgros O, Hervieu M, Osseby GV, Rouaud O, Giroud M: Prestroke antiplatelet therapy and early prognosis in stroke patients: the Dijon stroke registry. Eur J Neurol 2013;20:879-890.
4.
Zuliani G, Galvani M, Bonetti F, Prandini S, Magon S, Gasperini B, Ruggiero C, Cherubini A: Prior antiplatelet drug use and short-term mortality in older patients with acute ischemic stroke (AIS). Arch Gerontol Geriatr 2012;54:214-217.
5.
John S, Katzan I: Recurrent stroke while on antiplatelet therapy. Neurol Clin 2015;33:475-489.
6.
Yoon Y, Lee DH, Kang DW, Kwon SU, Suh DC, Bang OY, Kim JS: Stroke recurrence patterns are predicted by the subtypes and mechanisms of the past, non-cardiogenic stroke. Eur J Neurol 2013;20:928-934.
7.
Jung JM, Choi J, Eun MY, Seo WK, Cho KH, Yu S, Oh K, Hong S, Park KY: Prestroke antiplatelet agents in first-ever ischemic stroke: clinical effects. Neurology 2015;84:1080-1089.
8.
Jung JM, Kwon SU, Lee JH, Kang DW: Difference in infarct volume and patterns between cardioembolism and internal carotid artery disease: focus on the degree of cardioembolic risk and carotid stenosis. Cerebrovasc Dis 2010;29:490-496.
9.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke 1993;24:35-41.
10.
Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ: An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 2005;58:688-697.
11.
Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, Wolf PA: Infarcts of undetermined cause: the NINCDS stroke data bank. Ann Neurol 1989;25:382-390.
12.
Diener HC, Easton JD, Granger CB, Cronin L, Duffy C, Cotton D, Brueckmann M, Sacco RL; RE-SPECT ESUS Investigators: Design of randomized, double-blind, evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with embolic stroke of undetermined source (RE-SPECT ESUS). Int J Stroke 2015;10:1309-1312.
13.
Insull W Jr: The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med 2009;122(1 suppl):S3-S14.
14.
Ruggeri ZM: Platelets in atherothrombosis. Nat Med 2002;8:1227-1234.
15.
Micheli S, Corea F: Lacunar versus non-lacunar syndromes. Front Neurol Neurosci 2012;30:94-98.
16.
Lastilla M: Lacunar infarct. Clin Exp Hypertens 2006;28:205-215.
17.
Fisher CM: Capsular infarcts: the underlying vascular lesions. Arch Ne urol 1979;36:65-73.
18.
Kim JS: Small vessel disease: not a small problem. J Stroke 2015;17:1.
19.
Englyst NA, Horsfield G, Kwan J, Byrne CD: Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab 2008;28:1196-1203.
20.
Cho KH, Kim JS, Kwon SU, Cho AH, Kang DW: Significance of susceptibility vessel sign on T2*-weighted gradient echo imaging for identification of stroke subtypes. Stroke 2005;36:2379-2383.
21.
Zheng AS, Churilov L, Colley RE, Goh C, Davis SM, Yan B: Association of aspirin resistance with increased stroke severity and infarct size. JAMA Neurol 2013;70:208-213.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.